Savara (NASDAQ:SVRA) Receives Market Outperform Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Savara (NASDAQ:SVRA) in a report published on Tuesday, Benzinga reports. JMP Securities currently has a $9.00 price target on the stock.

A number of other research analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a buy rating and issued a $10.00 price objective on shares of Savara in a report on Tuesday. Oppenheimer upped their price target on Savara from $11.00 to $15.00 and gave the stock an outperform rating in a report on Wednesday, June 26th. Finally, Guggenheim raised their price objective on Savara from $8.00 to $10.00 and gave the company a buy rating in a report on Thursday, June 27th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Savara has a consensus rating of Buy and a consensus price target of $11.17.

Savara Stock Down 5.9 %

Shares of SVRA opened at $3.99 on Tuesday. The company has a market capitalization of $551.37 million, a price-to-earnings ratio of -10.78 and a beta of 0.97. Savara has a 52 week low of $3.12 and a 52 week high of $5.70. The stock’s 50-day moving average price is $4.32 and its 200-day moving average price is $4.45. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). On average, sell-side analysts predict that Savara will post -0.44 EPS for the current year.

Institutional Investors Weigh In On Savara

Institutional investors have recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co purchased a new position in shares of Savara in the first quarter valued at approximately $35,000. Choreo LLC acquired a new position in Savara in the 2nd quarter valued at $59,000. DRW Securities LLC purchased a new position in Savara in the 2nd quarter valued at $62,000. Principal Financial Group Inc. boosted its stake in Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares during the last quarter. Finally, Profund Advisors LLC purchased a new stake in shares of Savara during the second quarter worth $105,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.